124 related articles for article (PubMed ID: 33106847)
21. Effects of tissue decalcification on the quantification of breast cancer biomarkers by digital image analysis.
Gertych A; Mohan S; Maclary S; Mohanty S; Wawrowsky K; Mirocha J; Balzer B; Knudsen BS
Diagn Pathol; 2014 Nov; 9():213. PubMed ID: 25421113
[TBL] [Abstract][Full Text] [Related]
22. Receptor discordance rate and its effects on survival in primary and recurrent breast cancer patients.
Ilgun S; Sarsenov D; Erdogan Z; Ordu C; Celebi F; Nur Pilanci K; Ozturk A; Selamoglu D; Alco G; Aktepe F; Eralp Y; Tuzlali S; Ozmen V
J BUON; 2016; 21(6):1425-1432. PubMed ID: 28039703
[TBL] [Abstract][Full Text] [Related]
23. Breast density influences tumor subtypes and tumor aggressiveness.
Kerlikowske K; Phipps AI
J Natl Cancer Inst; 2011 Aug; 103(15):1143-5. PubMed ID: 21795663
[No Abstract] [Full Text] [Related]
24. Ribociclib in HR-positive, HER2-negative breast cancer.
Burki TK
Lancet Oncol; 2016 Nov; 17(11):e482. PubMed ID: 27746106
[No Abstract] [Full Text] [Related]
25. Potential therapeutic target for triple-negative breast cancer.
Gilbert JA
Lancet Oncol; 2012 Aug; 13(8):e330. PubMed ID: 23024992
[No Abstract] [Full Text] [Related]
26. Hormone Receptor and Human Epidermal Growth Factor Receptor 2 Detection in Invasive Breast Carcinoma: A Retrospective Study of 12,467 Patients From 19 Chinese Representative Clinical Centers.
Shui R; Liang X; Li X; Liu Y; Li H; Xu E; Zhang Z; Lian Y; Guo S; Yao M; Yang H; Xu F; Liu Y; Liu J; Guo D; Wang K; Li J; Ma Y; Wang J; Shi J; Bu H; Yang W
Clin Breast Cancer; 2020 Feb; 20(1):e65-e74. PubMed ID: 31669267
[TBL] [Abstract][Full Text] [Related]
27. The association of infrared imaging findings of the breast with hormone receptor and human epidermal growth factor receptor 2 status of breast cancer.
Wang J; Shih TT; Yen RF; Lu YS; Chen CY; Mao TL; Lin CH; Kuo WH; Tsai YS; Chang KJ; Chien KL
Acad Radiol; 2011 Feb; 18(2):212-9. PubMed ID: 21126889
[TBL] [Abstract][Full Text] [Related]
28. Association of breast cancer subtypes and body mass index.
Petekkaya I; Sahin U; Gezgen G; Solak M; Yuce D; Dizdar O; Arslan C; Ayyildiz V; Altundag K
Tumori; 2013; 99(2):129-33. PubMed ID: 23748802
[TBL] [Abstract][Full Text] [Related]
29. Human epidermal growth factor receptor 2 expression in breast cancer: correlation with clinical pathological features.
Ning SF; Li JL; Luo CP; Wei CH; Lu YK; Liu HZ; Wei WE; Zhang LT
Int J Clin Exp Pathol; 2014; 7(12):8740-7. PubMed ID: 25674240
[TBL] [Abstract][Full Text] [Related]
30. Assessment of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) status in the fine needle aspirates of metastatic breast carcinomas.
Monaco SE; Wu Y; Teot LA; Cai G
Diagn Cytopathol; 2013 Apr; 41(4):308-15. PubMed ID: 22045649
[TBL] [Abstract][Full Text] [Related]
31. Immunohistochemical detection of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression in breast carcinomas: comparison on cell block, needle-core, and tissue block preparations.
Hanley KZ; Birdsong GG; Cohen C; Siddiqui MT
Cancer; 2009 Aug; 117(4):279-88. PubMed ID: 19551847
[TBL] [Abstract][Full Text] [Related]
32. Basal-like immunophenotype markers and prognosis in early breast cancer.
Cassol L; Silveira Graudenz M; Zelmanowicz A; Cancela A; Werutsky G; Rovere RK; Garicochea B
Tumori; 2010; 96(6):966-70. PubMed ID: 21388060
[TBL] [Abstract][Full Text] [Related]
33. Modulating therapeutic effects of the c-Src inhibitor via oestrogen receptor and human epidermal growth factor receptor 2 in breast cancer cell lines.
Fan P; McDaniel RE; Kim HR; Clagett D; Haddad B; Jordan VC
Eur J Cancer; 2012 Dec; 48(18):3488-98. PubMed ID: 22658320
[TBL] [Abstract][Full Text] [Related]
34. Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastases.
Aitken SJ; Thomas JS; Langdon SP; Harrison DJ; Faratian D
Ann Oncol; 2010 Jun; 21(6):1254-1261. PubMed ID: 19858088
[TBL] [Abstract][Full Text] [Related]
35. Comparison of the expression of prognostic biomarkers between primary tumor and axillary lymph node metastases in breast cancer.
Zhao S; Xu L; Liu W; Lv C; Zhang K; Gao H; Wang J; Ma R
Int J Clin Exp Pathol; 2015; 8(5):5744-8. PubMed ID: 26191291
[TBL] [Abstract][Full Text] [Related]
36. The need to examine metastatic tissue at the time of progression of breast cancer: is re-biopsy a necessity or a luxury?
Khasraw M; Brogi E; Seidman AD
Curr Oncol Rep; 2011 Feb; 13(1):17-25. PubMed ID: 21053108
[TBL] [Abstract][Full Text] [Related]
37. Dual-energy CT quantitative parameters for evaluating Immunohistochemical biomarkers of invasive breast cancer.
Wang X; Liu D; Zeng X; Jiang S; Li L; Yu T; Zhang J
Cancer Imaging; 2021 Jan; 21(1):4. PubMed ID: 33413654
[TBL] [Abstract][Full Text] [Related]
38. Concordance of breast cancer biomarker status between routine immunohistochemistry/in situ hybridization and Oncotype DX qRT-PCR with investigation of discordance, a study of 591 cases.
Sechrist H; Glasgow A; Bomeisl P; Gilmore H; Harbhajanka A
Hum Pathol; 2020 Oct; 104():54-65. PubMed ID: 32758491
[TBL] [Abstract][Full Text] [Related]
39. Utility of estrogen receptor, progesterone receptor, and HER-2/neu analysis of multiple foci in multifocal ipsilateral invasive breast carcinoma.
East EG; Pang JC; Kidwell KM; Jorns JM
Am J Clin Pathol; 2015 Dec; 144(6):952-9. PubMed ID: 26573003
[TBL] [Abstract][Full Text] [Related]
40. Brief fixation enables same-day breast cancer diagnosis with reliable assessment of hormone receptors, E-cadherin and HER2/Neu.
Halilovic A; Bulte J; Jacobs Y; Braam H; van Cleef P; Schlooz-Vries M; Werner A; Boelens O; Nagtegaal I; de Wilt H; Bult P
J Clin Pathol; 2017 Sep; 70(9):781-786. PubMed ID: 28325747
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
